Non Invasive Prenatal Testing (NIPT) Market Worth $13.1 Billion by 2027
28 Jan 2020 • by Natalie Aster
Meticulous Research published a research report titled “Non Invasive Prenatal Testing (NIPT) Market by Product & Solution (Consumables, Systems, Software), Method (Ultrasound Screening, Cell Free DNA Test), Application (Trisomy, Microdeletions, Monosomy), and End-user (Diagnostic Labs) – Global Forecast to 2027”. According to this latest publication from Meticulous Research®, the global non-invasive prenatal testing market is expected to grow at a CAGR of 17.1% from 2019 to reach $13.1 billion by 2027.
The high growth of non-invasive prenatal testing market is mainly attributed to the high risk of chromosomal abnormalities with increasing maternal age, rise in occurrences of chromosomal aneuploidies among fetus, development of advanced and new technologies and non-invasive parenteral testing products, and improving reimbursement scenario for NIPT. In addition, rising awareness regarding non-invasive prenatal testing and untapped market opportunity in emerging markets offer significant growth opportunities for the players operating in this market. However, strict regulatory guidelines and ethical hurdles are some of the key factors challenging the adoption of non-invasive prenatal testing products over the coming years.
The global non-invasive prenatal testing market study presents historical market data in terms of values (2017 and 2018), estimated current data (2019), and forecasts for 2027- by product & solution (consumables, systems, software), method (ultrasound screening, cell free DNA test), application (trisomy, microdeletions, monosomy), and end-user. The study also evaluates industry competitors and analyzes the market at regional and country level.
On the basis of products and solutions, the kits/consumables segment commanded the largest share of the overall NIPT market in 2019, mainly due to increasing incidences of chromosomal abnormalities, rise in the number of tests and products for NIPT, and improvement of approvals or licenses for assays.
On the basis of application, trisomy segment accounted for the largest share of the overall NIPT market in 2019. The large share of this segment is mainly attributed to the factors such as the increasing maternal age and rising incidence of chromosomal abnormalities.
On the basis of end user, diagnostic laboratories segment accounted for the largest share of the overall NIPT market in 2019, as the large volume of NIPT testing done at diagnostic laboratories owing to availability of the well-equipped facility and availability of trained/skilled laboratory technicians. The initiatives taken by diagnostic laboratories to provide high quality testing services is further driving the growth in this market.
This research report analyzes major geographies and provides comprehensive analysis for North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, and RoAPAC), Latin America, and the Middle East & Africa. North America commanded the largest share of the global non-invasive prenatal testing market in 2019, followed by Europe and Asia-Pacific regions. High diagnostic and treatment rate of trisomy disorders and the emergence of key organizations in the U.S. are accelerating the non-invasive prenatal testing market in the North American region.
The key players operating in the global non-invasive prenatal testing market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), PerkinElmer, Inc. (Massachusetts), Illumina, Inc. (U.S.), Beijing Genomics Institute (China), Eurofins LifeCodexx AG (Germany), NATERA, INC. (U.S.), Igenomix SL (Spain), Laboratory Corporation of America Holdings (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), GE Healthcare (U.S.), and Yourgene Health (U.K.) among others.
More in-demand research reports by this publisher can be found in the Meticulous Market Research catalogue at MarketPublishers.com.